Altamira Therapeutics Ltd.
CYTOF evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CYTOF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CYTOF
Altamira Therapeutics Ltd. is a preclinical-stage biopharmaceutical company developing peptide-based nanoparticle delivery technologies for RNA therapeutics, with a focus on extrahepatic tissues and two proprietary programs in KRAS-driven cancer and rheumatoid arthritis.
Key risk: Preclinical stage only
Market Cap
$400K
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2025.
Altamira Therapeutics Ltd. is a preclinical-stage biopharmaceutical company developing peptide-based nanoparticle delivery technologies for RNA therapeutics, with a focus on extrahepatic tissues and two proprietary programs in KRAS-driven cancer and rheumatoid arthritis.
- Developing peptide-based nanoparticle technology (xPhore platform) for efficient RNA delivery to extrahepatic tissues [sec · filed 2025-04-30]
- Two proprietary preclinical programs: AM-401 for KRAS-driven cancer and AM-411 for rheumatoid arthritis, both beyond in vivo proof of concept [sec · filed 2025-04-30]
- Shareholders' equity of $4.1M and total debt of $0.7M as of 2025-06-30 [sec]
- Expects total additional cash need in 2024 of CHF 6.5 to 7.5 million, a substantial reduction from 2023 [sec · filed 2024-04-10]
What works
- Proprietary xPhore platform enables RNA delivery to extrahepatic tissues, potentially expanding therapeutic applications beyond liver-targeted approaches [sec · filed 2025-04-30]
- Two preclinical programs (AM-401, AM-411) have achieved in vivo proof of concept, indicating early validation of the technology [sec · filed 2025-04-30]
- Company has reduced cash burn by completing clinical development of Bentrio® and divesting part of that business, lowering expected 2024 cash needs to CHF 6.5–7.5 million [sec · filed 2024-04-10]
What to weigh
- All product candidates are still in preclinical development, with no guarantee of successful advancement to clinical trials or regulatory approval [sec · filed 2025-04-30]
- Company has a history of operating losses and needs substantial additional funding to continue development; inability to raise capital could materially affect operations [sec · filed 2024-04-10]
- Revenue generation depends entirely on out-licensing of platforms or programs, which is uncertain and may be delayed or unsuccessful [sec · filed 2025-04-30]
From the filings
Quoted directly from source documents.
Company is developing peptide-based nanoparticle technologies for RNA delivery to extrahepatic tissues
“developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (xPhore platform)”
SEC filings · April 30, 2025
AM-401 and AM-411 are in preclinical development beyond in vivo proof of concept
“AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept”
SEC filings · April 30, 2025
Company expects total additional cash need in 2024 of CHF 6.5 to 7.5 million
“We expect our total additional cash need in 2024 to be in the range of CHF 6.5 to 7.5 million”
SEC filings · April 10, 2024
Risks & what to watch (4)›
Key risks
- Preclinical stage only — All product candidates are in preclinical development; failure to advance could materially affect business [sec · filed 2025-04-30]
- Dependence on out-licensing
- Need for additional capital — Company needs substantial funding; inability to raise capital could halt operations [sec · filed 2024-04-10]
- Limited operating history — Company has a history of operating losses and limited history as a drug development-stage company [sec · filed 2024-04-10]
What to watch
- Progress of AM-401 and AM-411 preclinical programs toward IND or Phase 1 [sec · filed 2025-04-30]
- Ability to secure additional funding through licensing deals or capital raises [sec · filed 2024-04-10]
- Out-licensing of xPhore platform to biopharma partners [sec · filed 2025-04-30]
Sources: SEC filings · Generated August 28, 2026 · How we verify sources →
Run Altamira Therapeutics Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Altamira Therapeutics Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Short Interest
as of May 20, 2026- % of float
- 1.4%
- Days to cover
- 0.5
- Shares short
- 50,630
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CYTOF short interestFrequently asked questions
What is the AI investment thesis for Altamira Therapeutics Ltd.?
Altamira Therapeutics Ltd. is a preclinical-stage biopharmaceutical company developing peptide-based nanoparticle delivery technologies for RNA therapeutics, with a focus on extrahepatic tissues and two proprietary programs in KRAS-driven cancer and rheumatoid arthritis.
Who is the CEO of Altamira Therapeutics Ltd.?
Dr. Thomas Meyer Ph.D. is the chief executive officer of Altamira Therapeutics Ltd. (CYTOF).
Where is Altamira Therapeutics Ltd. headquartered?
Altamira Therapeutics Ltd. (CYTOF) is headquartered in Hamilton, Bermuda.
What therapeutic areas does Altamira Therapeutics Ltd. focus on?
Altamira Therapeutics Ltd. develops therapies across Ophthalmology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.